ArticleMedicine2026
Endoscopic endonasal resection of the cavernous sinus medial wall for functioning pituitary adenomas: A propensity score-matched retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Functioning pituitary adenomas (FPAs) account for 63% to 85% of pituitary adenomas. Although endoscopic endonasal surgery targets biochemical remission and reduced recurrence, cavernous sinus medial wall (CSMW) invasion often leads to incomplete resection and persistent disease. This retrospective study evaluated the clinical value of combining tumor excision with CSMW resection in patients with FPAs. We compared 60 patients who underwent tumor excision plus CSMW resection with contemporaneous controls who underwent tumor excision alone. Propensity scores based on age, sex, body mass index, Knosp grade, hormone subtype, and tumor size/volume were used for 1:1 nearest-neighbor matching, yielding 60 pairs. In the matched cohort, the CSMW resection group achieved higher sustained biochemical cure (≥6 months) (85.0% vs 61.7%) and clinical symptom relief (83.3% vs 56.7%), and a higher magnetic resonance imaging-defined gross total resection rate (95.0% vs 81.7%), with a lower recurrence rate (3.3% vs 15.0%) (all P < .05). After multivariable adjustment (age, sex, body mass index, and Knosp grade), CSMW resection remained independently associated with sustained biochemical cure (odds ratio [OR] = 4.77, 95% confidence interval [CI] 1.83-12.43), symptom relief (OR = 4.68, 95% CI 1.79-12.21), and gross total resection (OR = 4.55, 95% CI 1.04-19.95), and with reduced recurrence (OR = 0.16, 95% CI 0.03-0.78). Postoperative cerebrospinal fluid leakage and intracranial infection were less frequent with CSMW resection (both 3.3% vs 18.3%; OR = 0.13, 95% CI 0.03-0.54), whereas length of stay and other sinonasal complications did not differ materially. Tumor excision combined with CSMW resection may improve key clinical outcomes in FPAs and warrants consideration in appropriately selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.